Canadian opposition is a problem for U.S. lawmakers, who have argued
they can lower sky-high prescription drug prices by approving
imports from Canada, where prices are lower.
At least ten U.S. states, including Florida, have passed or proposed
laws to allow such imports, but actual shipments would not be legal
without federal approval. The U.S. Health and Human Services
secretary said last week the government was looking into ways to
import cheaper prescription drugs from overseas.
"Canada does not support actions that could adversely affect the
supply of prescription drugs in Canada and potentially raise costs
of prescription drugs for Canadians," reads an April briefing for
Canadian officials obtained under freedom of information laws.
The talking points, prepared by Canada's foreign ministry for use by
Canadian officials who speak with U.S. officials, cite research
suggesting shipments to the United States could cause shortages in
Canada.
Health Canada confirmed the government's position has not changed
since the talking points were prepared. The ministry said officials
have "made Canada's position clear" to both federal and state
officials in the United States and it stood ready to "take action to
ensure Canadians have uninterrupted access to the prescription drugs
they need."
U.S. drugmakers, keen to protect profits in the United States, their
most important market where prices are generally much higher, have
also argued against imports, saying they would put the safety of the
U.S. drug supply at risk. Health Canada says the Canadian drug
supply is safe.
The documents instruct Canadian officials to say that "importing
drugs from Canada is probably not your silver bullet." It suggests
noting that "there are other solutions" and offering to share the
ways Canada keeps healthcare costs low.
The issue may pose a fresh challenge to Canada's relationship with
U.S. President Donald Trump, while disruptions in the drug market
would be an unwelcome headache for Prime Minister Justin Trudeau's
government, especially ahead of Canada's October election.
In 2005, an earlier Canadian government promised a bill that would
restrict drug exports in response to similar U.S. proposals, but
never followed through.
[to top of second column] |
The Trump administration has promised to lower drug prices, but it
has failed to push through several initiatives, including forcing
drugmakers to disclose prices in TV ads and overhauling the system
of drug discounts.
U.S. Democrats see Trump as increasingly vulnerable to criticism on
healthcare costs. U.S. presidential contender Bernie Sanders has
offered several bills and amendments that would allow drug imports,
while Minnesota Senator Amy Klobuchar recently announced a drug
price plan that would include letting patients order drugs from
countries like Canada.
Sanders is set to join a group of U.S. patients traveling to
Windsor, Ontario, to buy cheap insulin later this month.
The documents say the U.S. proposals have not been detailed enough
to properly assess impact, but cite a study from 2010 which
estimated that if 10% of U.S. prescriptions were filled from Canada,
the drug supply would run out in 224 days.
They also note there are already barriers to shipping drugs from
Canada to the United States. For example, many purchase agreements
forbid the re-export of drugs.
Most of the entities that regulate Canadian pharmacists forbid
filling prescriptions written by foreign doctors, but some Canadian
pharmacies do ship across the border. The U.S. Food and Drug
Administration does not generally block small-scale imports for
personal use.
Innovative Medicines Canada, which represents drugmakers including
the major U.S. manufacturers, said it is concerned about the import
proposals, and raised the issue with Health Canada.
"Canada cannot supply medicines and vaccines to a market ten times
larger than its own population without jeopardizing Canadian
supplies and causing shortages," the organization said in a
statement.
(Additional reporting by Caroline Humer in New York; Editing by
Amran Abocar and Chris Reese)
[© 2019 Thomson Reuters. All rights
reserved.] Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |